| Date: 20/11/2023 |
|--|
| Your Name: Daisuke Nishigake |
| Manuscript Title: Influence of cardiac cycle on myocardial extracellular volume fraction |
| measurements with dual-layer computed tomography |
| Manuscript number (if known): |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present | _ ☑ None | |
| | manuscript (e.g., funding, | | |
| | provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | None | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | _ <u>✓</u> None | |
| | | | |
| | | | |
| 4 | Consulting fees | _ <u>✓</u> None | |
| | | | |

| 5 | Payment or honoraria for | ✓ None | |
|----|---|-----------------|--|
| | lectures, presentations, | | |
| | speakers bureaus, | | |
| | manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | _ <u> </u> | |
| | testimony | | |
| | | | |
| 7 | Support for attending meetings and/or travel | _ <u> </u> | |
| | | | |
| | | | |
| 8 | Patents planned, issued or | _ <u> </u> | |
| | pending | | |
| | | | |
| 9 | Participation on a Data | <u> </u> | |
| | Safety Monitoring Board or | | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | None | |
| | in other board, society, | | |
| | committee or advocacy | | |
| 11 | group, paid or unpaid | | |
| 11 | Stock or stock options | None | |
| | | | |
| 12 | Receipt of equipment, | ☑ None | |
| | materials, drugs, medical | | |
| | writing, gifts or other | | |
| | services | | |
| 13 | Other financial or non- | _ <u> </u> None | |
| | financial interests | | |
| | | | |

The author has no conflicts of interest.

Please place an "X" next to the following statement to indicate your agreement:

| Date: 20/11/2023 |
|--|
| Your Name: Yuzo Yamasaki |
| Manuscript Title: Influence of cardiac cycle on myocardial extracellular volume fraction |
| measurements with dual-layer computed tomography |
| Manuscript number (if known): |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present | None | |
| | manuscript (e.g., funding, | | |
| | provision of study materials, medical writing, article processing charges, etc.) | The Japan Society of the Promotion of Science (JSPS) | Research grant KAKENHI(20K16728 and 23K07111) |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | None | |
| | any entity (if not indicated | KONICAMINOLTA, INC. | Research grant |
| | in item #1 above). | Konica Minolta Science | Research grant |
| | | and Technology | |
| | | Foundation | |
| 3 | Royalties or licenses | _ <u>☑</u> None | |

| 4 | Consulting fees | <u>_</u> None | |
|----|--|--------------------|------------------------|
| | | | |
| 5 | Payment or honoraria for | None | |
| - | lectures, presentations, | KONICAMINOLTA, INC | Honoraria for lectures |
| | speakers bureaus, | | |
| | manuscript writing or | | |
| 6 | educational events Payment for expert | ☑ None | |
| D | testimony | | |
| | | | |
| 7 | Support for attending meetings and/or travel | _☑ None | |
| | | | |
| | | | |
| 8 | Patents planned, issued or | _ <u> </u> | |
| | pending | | |
| 9 | Participation on a Data | None | |
| 5 | Safety Monitoring Board or | | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | _ ☑ None | |
| | in other board, society, | | |
| | committee or advocacy group, paid or unpaid | | |
| 11 | Stock or stock options | <u>_</u> None | |
| | | | |
| 12 | Dessint of any imment | | |
| 12 | Receipt of equipment, materials, drugs, medical | None | |
| | writing, gifts or other | | |
| | services | | |
| 13 | Other financial or non- | _☑ None | |
| | financial interests | | |
| | | | |

The author received research grants from JSPS (KAKENHI), KONICAMINOLTA, INC, and

Konica Minolta Science and Technology Foundation; and Honoraria for lectures from

KONICAMINOLTA, INC.

Please place an "X" next to the following statement to indicate your agreement:

| Date: 20/11/2023 | | |
|--|--|--|
| Your Name: Tomoyuki Hida | | |
| Manuscript Title: Influence of cardiac cycle on myocardial extracellular volume fraction | | |
| measurements with dual-layer computed tomography | | |
| Manuscript number (if known): | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present | _☑ None | |
| | manuscript (e.g., funding, | | |
| | provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) No time limit for this item. | | |
| | No time mint for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | None | |
| | any entity (if not indicated | The Japan Society of the | Reseach grant for KAKENHI(20K16827) |
| | in item #1 above). | Promotion of Science | |
| | | (JSPS) | |
| | | | |
| 3 | Royalties or licenses | _ <u>_</u> None | |
| | | | |
| | | | |

| 4 | Consulting fees | _ <u>√</u> None | |
|-----|--|-----------------|--|
| | | | |
| | | | |
| 5 | Payment or honoraria for | ✓ None | |
| | lectures, presentations, | | |
| | speakers bureaus, | | |
| | manuscript writing or | | |
| 6 | educational events Payment for expert | ☑ None | |
| 0 | testimony | | |
| | testimony | | |
| 7 | Support for attending | ☑ None | |
| , í | meetings and/or travel | | |
| | | | |
| | | | |
| | | | |
| 8 | Patents planned, issued or | <u>_</u> None | |
| | pending | | |
| 9 | Participation on a Data | None | |
| 9 | Safety Monitoring Board or | | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | ☑ None | |
| | in other board, society, | | |
| | committee or advocacy | | |
| | group, paid or unpaid | | |
| 11 | Stock or stock options | <u>_</u> None | |
| | | | |
| | | | |
| 12 | Receipt of equipment, | <u>_</u> None | |
| | materials, drugs, medical | | |
| | writing, gifts or other services | | |
| 13 | Other financial or non- | _ <u> </u> None | |
| | financial interests | | |
| | | | |

The author recieved a reseach grant KAKENHI from JSPS.

Please place an "X" next to the following statement to indicate your agreement:

| Date: 20/11/2023 |
|--|
| Your Name: Takashi Shirasaka |
| Manuscript Title: Influence of cardiac cycle on myocardial extracellular volume fraction |
| measurements with dual-layer computed tomography |
| Manuscript number (if known): |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | _ <u> </u> None | |
| 3 | Royalties or licenses | _ ☑ None | |
| 4 | Consulting fees | _☑ None | |

| 5 | Payment or honoraria for | ✓ None | |
|----|---|-----------------|--|
| | lectures, presentations, | | |
| | speakers bureaus, | | |
| | manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | _ <u> </u> | |
| | testimony | | |
| | | | |
| 7 | Support for attending meetings and/or travel | _ <u> </u> | |
| | | | |
| | | | |
| 8 | Patents planned, issued or | _ <u> </u> | |
| | pending | | |
| | | | |
| 9 | Participation on a Data | <u> </u> | |
| | Safety Monitoring Board or | | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | None | |
| | in other board, society, | | |
| | committee or advocacy | | |
| 11 | group, paid or unpaid | | |
| 11 | Stock or stock options | None | |
| | | | |
| 12 | Receipt of equipment, | ☑ None | |
| | materials, drugs, medical | | |
| | writing, gifts or other | | |
| | services | | |
| 13 | Other financial or non- | _ <u> </u> None | |
| | financial interests | | |
| | | | |

The author has no conflicts of interest.

Please place an "X" next to the following statement to indicate your agreement:

| Date: 20/11/2023 |
|--|
| Your Name: <u>Ryohei Funatsu</u> |
| Manuscript Title: Influence of cardiac cycle on myocardial extracellular volume fraction |
| measurements with dual-layer computed tomography |
| Manuscript number (if known): |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) | |
|---|-------------------------------|--|---|--|
| | | Time frame: Since the initial | planning of the work | |
| 1 | All support for the present | None | | |
| | manuscript (e.g., funding, | | | |
| | provision of study materials, | | | |
| | medical writing, article | | | |
| | processing charges, etc.) | | | |
| | No time limit for this item. | | | |
| | | | | |
| | | | | |
| | Time frame: past 36 months | | | |
| 2 | Grants or contracts from | None | | |
| | any entity (if not indicated | | | |
| | in item #1 above). | | | |
| 3 | Royalties or licenses | None | | |
| | | | | |
| | | | | |
| 4 | Consulting fees | None | | |
| | _ | _ | | |

| 5 | Payment or honoraria for | ✓ None | |
|----|---|-----------------|--|
| | lectures, presentations, | | |
| | speakers bureaus, | | |
| | manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | _ <u> </u> | |
| | testimony | | |
| | | | |
| 7 | Support for attending meetings and/or travel | _ <u> </u> | |
| | | | |
| | | | |
| 8 | Patents planned, issued or | _ <u> </u> | |
| | pending | | |
| | | | |
| 9 | Participation on a Data | <u> </u> | |
| | Safety Monitoring Board or | | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | None | |
| | in other board, society, | | |
| | committee or advocacy | | |
| 11 | group, paid or unpaid | | |
| 11 | Stock or stock options | None | |
| | | | |
| 12 | Receipt of equipment, | ☑ None | |
| | materials, drugs, medical | | |
| | writing, gifts or other | | |
| | services | | |
| 13 | Other financial or non- | _ <u> </u> None | |
| | financial interests | | |
| | | | |

The author has no conflicts of interest.

Please place an "X" next to the following statement to indicate your agreement:

| Date: 20/11/2023 | | |
|--|--|--|
| Your Name: Toyoyuki Kato | | |
| Manuscript Title: Influence of cardiac cycle on myocardial extracellular volume fraction | | |
| measurements with dual-layer computed tomography | | |
| Manuscript number (if known): | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present | <u> </u> | |
| | manuscript (e.g., funding, | | |
| | provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) No time limit for this item. | | |
| | No time mint for this item. | | |
| | | | |
| | | T : | |
| - | | Time frame: past | 36 months |
| 2 | Grants or contracts from | None | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | _ <u>√</u> None | |
| | | | |
| | | | |
| 4 | Consulting fees | _ <u>✓</u> None | |
| | | | |

| 5 | Payment or honoraria for | ✓ None | |
|----|---|-----------------|--|
| | lectures, presentations, | | |
| | speakers bureaus, | | |
| | manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | _ <u> </u> | |
| | testimony | | |
| | | | |
| 7 | Support for attending meetings and/or travel | None | |
| | | | |
| | | | |
| 8 | Patents planned, issued or | _ <u> </u> | |
| | pending | | |
| | | | |
| 9 | Participation on a Data | <u> </u> | |
| | Safety Monitoring Board or | | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | None | |
| | in other board, society, | | |
| | committee or advocacy | | |
| 11 | group, paid or unpaid | | |
| 11 | Stock or stock options | None | |
| | | | |
| 12 | Receipt of equipment, | ☑ None | |
| | materials, drugs, medical | | |
| | writing, gifts or other | | |
| | services | | |
| 13 | Other financial or non- | _ <u> </u> None | |
| | financial interests | | |
| | | | |

The author has no conflicts of interest.

Please place an "X" next to the following statement to indicate your agreement:

| Date: 20/11/2023 | | |
|--|--|--|
| Your Name: Kousei Ishigami | | |
| Manuscript Title: Influence of cardiac cycle on myocardial extracellular volume fraction | | |
| measurements with dual-layer computed tomography | | |
| Manuscript number (if known): | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) | |
|---|-------------------------------|--|---|--|
| | | Time frame: Since the initial | planning of the work | |
| 1 | All support for the present | _ ☑ None | | |
| | manuscript (e.g., funding, | | | |
| | provision of study materials, | | | |
| | medical writing, article | | | |
| | processing charges, etc.) | | | |
| | No time limit for this item. | | | |
| | | | | |
| | | | | |
| | Time frame: past 36 months | | | |
| 2 | Grants or contracts from | None | | |
| | any entity (if not indicated | | | |
| | in item #1 above). | | | |
| 3 | Royalties or licenses | _ <u>✓</u> None | | |
| | | | | |
| | | | | |
| 4 | Consulting fees | _ <u>✓</u> None | | |
| | | | | |

| 5 | Payment or honoraria for | ✓ None | |
|----|---|-----------------|--|
| | lectures, presentations, | | |
| | speakers bureaus, | | |
| | manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | _ <u> </u> | |
| | testimony | | |
| | | | |
| 7 | Support for attending meetings and/or travel | _ <u> </u> | |
| | | | |
| | | | |
| 8 | Patents planned, issued or | _ <u> </u> | |
| | pending | | |
| | | | |
| 9 | Participation on a Data | <u> </u> | |
| | Safety Monitoring Board or | | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | None | |
| | in other board, society, | | |
| | committee or advocacy | | |
| 11 | group, paid or unpaid | | |
| 11 | Stock or stock options | None | |
| | | | |
| 12 | Receipt of equipment, | ☑ None | |
| | materials, drugs, medical | | |
| | writing, gifts or other | | |
| | services | | |
| 13 | Other financial or non- | _ <u> </u> None | |
| | financial interests | | |
| | | | |

The author has no conflicts of interest.

Please place an "X" next to the following statement to indicate your agreement: